NIKKEI 225
38,837.46 -85.54 (-0.22%) HANG SENG
18,444.11 +41.11 (+0.22%) CRUDE OIL
73.40 -0.82 (-1.10%) GOLD FUTURES
2,347.60 -21.70 (-0.92%) DOW
38,621.14 +50.11 (+0.13%) Bitcoin GBP
55,303.45 +1,147.42 (+2.12%)
AZN Jan 2026 85.000 call
| Previous close | 8.15 |
| Open | 8.23 |
| Bid | 8.45 |
| Ask | 8.85 |
| Strike | 85.00 |
| Expiry date | 2026-01-16 |
| Day's range | 8.15 - 8.23 |
| Contract range | N/A |
| Volume | |
| Open interest | 148 |
PR NewswireAbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024
AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced preliminary safety and efficacy results from its first time in human investigator-initiated trial (IIT) of C-CAR031 in connection with the Company's oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation shared data indicati
ZacksAstrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Astrazeneca (AZN) closed at $78.99, marking a +1.24% move from the previous day.
Business WireTAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
WILMINGTON, Del., June 02, 2024--Positive results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose tumors have exon 19 deletions or exon 21 (L858R) mutations, after chemoradiotherapy (CRT) compared to placebo after CRT.
